Reviewing Immatics (NASDAQ:IMTX) and MiMedx Group (NASDAQ:MDXG)

Immatics (NASDAQ:IMTX) and MiMedx Group (NASDAQ:MDXG) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, valuation, institutional ownership, earnings, dividends, profitability and analyst recommendations.

Valuation and Earnings

This table compares Immatics and MiMedx Group”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immatics	$54.60 million	22.20	-$222.26 million	($1.86)	-4.77
MiMedx Group	$418.63 million	1.63	$48.58 million	$0.04	116.88

MiMedx Group has higher revenue and earnings than Immatics. Immatics is trading at a lower price-to-earnings ratio than MiMedx Group, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Immatics and MiMedx Group’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Immatics	-495.71%	-47.41%	-39.45%
MiMedx Group	1.76%	12.09%	9.22%

Insider & Institutional Ownership

64.4% of Immatics shares are held by institutional investors. Comparatively, 79.2% of MiMedx Group shares are held by institutional investors. 2.5% of MiMedx Group shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of recent ratings for Immatics and MiMedx Group, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immatics	1	1	6	0	2.62
MiMedx Group	1	0	6	0	2.71

Immatics presently has a consensus target price of $20.60, indicating a potential upside of 132.27%. MiMedx Group has a consensus target price of $8.57, indicating a potential upside of 83.35%. Given Immatics’ higher possible upside, research analysts plainly believe Immatics is more favorable than MiMedx Group.

Volatility and Risk

Immatics has a beta of 1.33, meaning that its stock price is 33% more volatile than the S&P 500. Comparatively, MiMedx Group has a beta of 1.43, meaning that its stock price is 43% more volatile than the S&P 500.

Summary

MiMedx Group beats Immatics on 11 of the 13 factors compared between the two stocks.

About Immatics

Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its products pipeline includes IMA203 that targets solid tumors, which is in Phase 1b clinical trial; IMA203CD8, a cell therapy product that is in Phase 1b clinical trial; IMA204 that targets tumor stroma, which is in preclinical stage; and IMA30x, an allogenic cellular therapy product candidate, which is in preclinical stage. The company also develops TCR Bispecifics products, including IMA401 and IMA402, which is in Phase 1a clinical trial. The company has a strategic collaboration agreement with MD Anderson Cancer Center to develop multiple T cell and TCR-based adoptive cellular therapies; Celgene Corporation to develop novel adoptive cell therapies targeting multiple cancers; and Genmab A/S to develop T cell engaging bispecific immunotherapies targeting multiple cancer indications. Immatics N.V. is headquartered in Tübingen, Germany.

About MiMedx Group

MiMedx Group, Inc. develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue’s inherent biological properties and regulatory proteins. The company’s patented and proprietary processing method employs aseptic processing techniques in addition to terminal sterilization. Its products include EpiFix, a barrier membrane allograft used for the treatment of chronic wounds, including diabetic foot ulcers, venous leg ulcers, and pressure ulcers; AmnioFix, a protective barrier allograft, which comprises dehydrated human amnion/chorion membrane for use in surgical recovery applications; and EpiCord and AmnioCord are dehydrated human umbilical cord allografts that are used to provide a protective environment for the healing process, as well as used in the advanced wound care and surgical recovery applications. The company’s products have applications in the areas of wound care, burn, surgical sectors of healthcare. The company sells its products through direct sales force and independent sales agents, as well as through independent distributors primarily in the United States. MiMedx Group, Inc. was founded in 2006 and is headquartered in Marietta, Georgia.